{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:02:24Z","timestamp":1762866144989},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,2,17]],"date-time":"2013-02-17T00:00:00Z","timestamp":1361059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,2,17]],"date-time":"2013-02-17T00:00:00Z","timestamp":1361059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s10637-013-9934-y","type":"journal-article","created":{"date-parts":[[2013,2,16]],"date-time":"2013-02-16T08:49:17Z","timestamp":1361004557000},"page":"1016-1022","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors"],"prefix":"10.1007","volume":"31","author":[{"given":"Darren R.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H.","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnathan K.","family":"Joffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Hajdenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel-Baset","family":"Halim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamim","family":"Zahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,17]]},"reference":[{"key":"9934_CR1","unstructured":"National Comprehensive Cancer Network (2011) NCCN clinical practice guidelines in oncology, testicular cancer, version 2.2011. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed December 6, 2012"},{"key":"9934_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1071-5576(97)00111-1","volume":"5","author":"M Lail-Trecker","year":"1998","unstructured":"Lail-Trecker M, Gulati R, Peluso JJ (1998) A role for hepatocyte growth factor\/scatter factor in regulating normal and neoplastic cells of reproductive tissues. J Soc Gynecol Investig 5:114\u2013121. doi:10.1016\/S1071-5576(98)00002-1","journal-title":"J Soc Gynecol Investig"},{"key":"9934_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E","volume":"74","author":"L Beviglia","year":"1997","unstructured":"Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH (1997) Expression of the c-Met\/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 74:301\u2013309. doi:10.1002\/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E","journal-title":"Int J Cancer"},{"key":"9934_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/jcb.10239","volume":"86","author":"H Qiao","year":"2002","unstructured":"Qiao H, Hung W, Tremblay E et al (2002) Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem 86:665\u2013677. doi:10.1002\/jcb.10239","journal-title":"J Cell Biochem"},{"key":"9934_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1073\/pnas.94.2.701","volume":"94","author":"H Takayama","year":"1997","unstructured":"Takayama H, LaRochelle WJ, Sharp R et al (1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor\/scatter factor. Proc Natl Acad Sci U S A 94:701\u2013706","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9934_CR6","first-page":"1480","volume":"9","author":"H Takeuchi","year":"2003","unstructured":"Takeuchi H, Bilchik A, Saha S et al (2003) c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9:1480\u20131488","journal-title":"Clin Cancer Res"},{"key":"9934_CR7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.ejca.2010.02.028","volume":"46","author":"F Cecchi","year":"2010","unstructured":"Cecchi F, Rabe DC, Bottaro DP (2010) Targeting the HGF\/Met signalling pathway in cancer. Eur J Cancer 46:1260\u20131270. doi:10.1016\/j.ejca.2010.02.028","journal-title":"Eur J Cancer"},{"key":"9934_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/1758834011408636","volume":"3","author":"M Sattler","year":"2011","unstructured":"Sattler M, Hasina R, Reddy MM, Gangadhar T, Salgia R (2011) The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 3:171\u2013184. doi:10.1177\/1758834011408636","journal-title":"Ther Adv Med Oncol"},{"key":"9934_CR9","unstructured":"Daiichi Sankyo Inc (2009) Data on file"},{"key":"9934_CR10","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-09-1173","volume":"9","author":"N Munshi","year":"2010","unstructured":"Munshi N, Jeay S, Li Y et al (2010) ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9:1544\u20131553","journal-title":"Mol Cancer Ther"},{"key":"9934_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1634\/theoncologist.2010-0380","volume":"16","author":"AA Adjei","year":"2011","unstructured":"Adjei AA, Schwartz B, Garmey E (2011) Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist 16:788\u2013799. doi:10.1634\/theoncologist.2010-0380","journal-title":"Oncologist"},{"key":"9934_CR12","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.1158\/1078-0432.CCR-11-1002","volume":"17","author":"LS Rosen","year":"2011","unstructured":"Rosen LS, Senzer N, Mekhail T et al (2011) A phase I dose-escalation study of tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 17:7754\u20137764","journal-title":"Clin Cancer Res"},{"key":"9934_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"9934_CR14","doi-asserted-by":"crossref","unstructured":"Mekhail T, Rich T, Rosen L et al. (2009) Final results: a dose escalation phase I study of ARQ 197, a selective c-MET inhibitor, in patients with metastatic solid tumors. J Clin Oncol 27:Abstract 3548","DOI":"10.1200\/jco.2009.27.15_suppl.3548"},{"key":"9934_CR15","unstructured":"Daiichi Sankyo Inc (2011) ARQ 197 for subjects with relapsed or refractory germ cell tumors. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01055067. Accessed December 6, 2012"},{"key":"9934_CR16","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1200\/JCO.2010.31.0367","volume":"29","author":"TA Yap","year":"2011","unstructured":"Yap TA, Olmos D, Brunetto AT et al (2011) Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29:1271\u20131279. doi:10.1200\/JCO.2010.31.0367","journal-title":"J Clin Oncol"},{"key":"9934_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/cncr.26375","volume":"118","author":"DR Feldman","year":"2012","unstructured":"Feldman DR, Patil S, Trinos MJ et al (2012) Progression-free and overall survival in patients with relapsed\/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer 118:981\u2013986. doi:10.1002\/cncr.26375","journal-title":"Cancer"},{"key":"9934_CR18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/jcp.48.9.876","volume":"48","author":"S Detre","year":"1995","unstructured":"Detre S, Saclani Jotti G, Dowsett M (1995) A \u201cquickscore\u201d method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48:876\u2013878","journal-title":"J Clin Pathol"},{"key":"9934_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa067749","volume":"357","author":"LH Einhorn","year":"2007","unstructured":"Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R (2007) High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357:340\u2013348. doi:10.1056\/NEJMoa067749","journal-title":"N Engl J Med"},{"key":"9934_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1200\/JCO.2006.06.9401","volume":"25","author":"GV Kondagunta","year":"2007","unstructured":"Kondagunta GV, Bacik J, Sheinfeld J et al (2007) Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 25:85\u201390. doi:10.1200\/JCO.2006.06.9401","journal-title":"J Clin Oncol"},{"key":"9934_CR21","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.eururo.2006.05.011","volume":"50","author":"U De Giorgi","year":"2006","unstructured":"De Giorgi U, Rosti G, Aieta M et al (2006) Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol 50:1032\u20131038. doi:10.1016\/j.eururo.2006.05.011, discussion 1038\u20131039","journal-title":"Eur Urol"},{"key":"9934_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JCO.2004.06.068","volume":"22","author":"C Kollmannsberger","year":"2004","unstructured":"Kollmannsberger C, Beyer J, Liersch R et al (2004) Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 22:108\u2013114. doi:10.1200\/JCO.2004.06.068","journal-title":"J Clin Oncol"},{"key":"9934_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/annonc\/mdh103","volume":"15","author":"D Pectasides","year":"2004","unstructured":"Pectasides D, Pectasides M, Farmakis D et al (2004) Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 15:493\u2013497","journal-title":"Ann Oncol"},{"key":"9934_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi E, Birchmeier W, Birchmeier C, Woude GV (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89\u2013103. doi:10.1038\/nrc3205","journal-title":"Nat Rev Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-9934-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9934-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:37:09Z","timestamp":1678509429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-9934-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,17]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["9934"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-9934-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,17]]},"assertion":[{"value":"7 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}